Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Novel Coronavirus Disease (COVID-19): A Narrative Review Based on Current Status

Author(s): Rina Das, Dinesh K. Mehta* and Meenakshi Dhanawat

Volume 19, Issue 3, 2021

Published on: 20 October, 2020

Page: [267 - 277] Pages: 11

DOI: 10.2174/2211352518999201020202540

Price: $65

Abstract

A novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared and expanded globally by the end of the year 2019 from Wuhan, China, causing the severe acute respiratory syndrome. During its initial stage, the disease was called the novel coronavirus (2019-nCoV). It was named COVID-19 by the World Health Organization (WHO) on 11th February, 2020. The WHO declared the SARS-CoV-2 virus a pandemic in March 2020. On 30th January, 2020, the first case of Corona Virus Disease 2019 (COVID-19) was reported in India. Currently, the virus has spread to almost every part of the province and the rest of the globe.

On the basis of novel published evidence, we efficiently summarized the reported work with reference to COVID-19 epidemiology, pathogen, clinical symptoms, treatment, and prevention. Several worldwide electronic scientific databases such as Pubmed, Medline, Embase, Science Direct, Scopus, etc., were utilized for extensive investigation of relevant literature.

This review is written in the hope of encouraging people with the key learning points from the underway efforts to perceive and manage SARS-CoV-2, suggesting salient points for expanding future research.

Keywords: Corona, nCoV, COVID-19, SARS-CoV-2, prevention, respiratory, symptoms, treatment.

Graphical Abstract

[1]
Lu, H.; Stratton, C.W.; Tang, Y.W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J. Med. Virol., 2020, 92(4), 401-402.
[http://dx.doi.org/10.1002/jmv.25678] [PMID: 31950516]
[2]
Kachroo, V. Novel Coronavirus (COVID-19) in India: Current Scenario. International Journal of Research and Review., 2020, 7(3), 435-447.
[3]
Liu, Q.; Xu, K.; Wang, X.; Wang, W. From SARS to COVID-19: What lessons have we learned? J. Infect. Public Health, 2020, S1876-0341(20)30600-6.
[http://dx.doi.org/10.1016/j.jiph.2020.08.001] [PMID: 32888871]
[4]
Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X.; Zheng, X.S.; Zhao, K.; Chen, Q.J.; Deng, F.; Liu, L.L.; Yan, B.; Zhan, F.X.; Wang, Y.Y.; Xiao, G.F.; Shi, Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798), 270-273.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[5]
Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W.J.; Wang, D.; Xu, W.; Holmes, E.C.; Gao, G.F.; Wu, G.; Chen, W.; Shi, W.; Tan, W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020, 395(10224), 565-574.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]
[6]
Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10223), 507-513.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[7]
Novel Corona Virus: Situation Report 2020.https://www.who.int/docs/default‐source/
[8]
Perlman, S.; Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol., 2009, 7(6), 439-450.
[http://dx.doi.org/10.1038/nrmicro2147] [PMID: 19430490]
[9]
Cheng, V.C.; Lau, S.K.; Woo, P.C.; Yuen, K.Y. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev., 2007, 20(4), 660-694.
[http://dx.doi.org/10.1128/CMR.00023-07] [PMID: 17934078]
[10]
Chan, J.F.; Lau, S.K.; To, K.K.; Cheng, V.C.; Woo, P.C.; Yuen, K.Y. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev., 2015, 28(2), 465-522.
[http://dx.doi.org/10.1128/CMR.00102-14] [PMID: 25810418]
[11]
Peiris, J.S.; Lai, S.T.; Poon, L.L.; Guan, Y.; Yam, L.Y.; Lim, W.; Nicholls, J.; Yee, W.K.; Yan, W.W.; Cheung, M.T.; Cheng, V.C.; Chan, K.H.; Tsang, D.N.; Yung, R.W.; Ng, T.K.; Yuen, K.Y. SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 2003, 361(9366), 1319-1325.
[http://dx.doi.org/10.1016/S0140-6736(03)13077-2] [PMID: 12711465]
[12]
Zaki, A.M. Van, Boheemen S.; Beteboroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of novel coronavirus from a man with pneumonia in Saudi Arabia (published correction appears in N Eng J of Med, 2013,369:394]. N. Engl. J. Med., 2012, 367, 1814-1820.
[http://dx.doi.org/10.1056/NEJMoa1211721] [PMID: 23075143]
[13]
Gralinski, L.E.; Baric, R.S. Molecular pathology of emerging coronavirus infections. J. Pathol., 2015, 235(2), 185-195.
[http://dx.doi.org/10.1002/path.4454] [PMID: 25270030]
[14]
Drosten, C.; Günther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R.A.; Berger, A.; Burguière, A.M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J.C.; Müller, S.; Rickerts, V.; Stürmer, M.; Vieth, S.; Klenk, H.D.; Osterhaus, A.D.; Schmitz, H.; Doerr, H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med., 2003, 348(20), 1967-1976.
[http://dx.doi.org/10.1056/NEJMoa030747] [PMID: 12690091]
[15]
Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol., 2020, 92(4), 418-423.
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[16]
Jeong, Y.S. 2019 novel coronavirus disease outbreak and molecular genetic characteristics of severe acute respiratory syndrome-coronavirus-2. J. Bacteriol. Virol., 2020, 50(1), 1-8.
[http://dx.doi.org/10.4167/jbv.2020.50.1.001]
[17]
Di Gennaro, F.; Pizzol, D.; Marotta, C.; Antunes, M.; Racalbuto, V.; Veronese, N.; Smith, L. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int. J. Environ. Res. Public Health, 2020, 17(8), 1-11.
[http://dx.doi.org/10.3390/ijerph17082690] [PMID: 32295188]
[18]
Yin, Y.; Wunderink, R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 2018, 23(2), 130-137.
[http://dx.doi.org/10.1111/resp.13196] [PMID: 29052924]
[19]
Liu, J.; Zheng, X.; Tong, Q.; Li, W.; Wang, B.; Sutter, K.; Trilling, M.; Lu, M.; Dittmer, U.; Yang, D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J. Med. Virol., 2020, 92(5), 491-494.
[http://dx.doi.org/10.1002/jmv.25709] [PMID: 32056249]
[20]
Zumla, A.; Chan, J.F.; Azhar, E.I.; Hui, D.S.; Yuen, K.Y. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov., 2016, 15(5), 327-347.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[21]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[22]
Paules, C.I.; Marston, H.D.; Fauci, A.S. Corona virus infection – more than just the common cold. JAMA, 2020, 323(8), 707-708.
[http://dx.doi.org/10.1001/jama.2020.0757] [PMID: 31971553]
[23]
Raj, V.S.; Mou, H.; Smits, S.L.; Dekkers, D.H.; Müller, M.A.; Dijkman, R.; Muth, D.; Demmers, J.A.; Zaki, A.; Fouchier, R.A.; Thiel, V.; Drosten, C.; Rottier, P.J.; Osterhaus, A.D.; Bosch, B.J.; Haagmans, B.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 2013, 495(7440), 251-254.
[http://dx.doi.org/10.1038/nature12005] [PMID: 23486063]
[24]
Hoffmann, M; Kleine-Weber, H; Krüger, N; Müller, M; Drosten, C; Pöhlmann, S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Bio Rxiv., 2020.
[25]
He, Y.; Zhou, Y.; Liu, S.; Kou, Z.; Li, W.; Farzan, M.; Jiang, S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun., 2004, 324(2), 773-781.
[http://dx.doi.org/10.1016/j.bbrc.2004.09.106] [PMID: 15474494]
[26]
Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483), 1260-1263.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[27]
Heng, Li.; Ming Liu, Shang; Hua Yu, Xiao.; Tang, Shi-Lin.; Tang, Chao-Ke . Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int. J. Antimicrob. Agents, 2020, 20, 54.
[28]
Feng, Hi.; Deng, Yu.; Weina, Li. Coronavirus disease 2019: What we know? J. Med. Virol., 2020, 92(7), 719-725.
[29]
WHO Director-General Speeches. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020
[30]
Home | Ministry of Health and Family Welfare | GOI Available from: mohfw.gov.in
[31]
Sinha, A. One COVID-19 positive infects 1.7 in India, lower than in hot zones. The Indian Express, 2020. Available from: https://indianexpress.com/article/coronaviru s/coronavirus-india-infection-rate-china6321154/
[32]
Ramesh, Sandhya R0 data shows India's coronavirus infection rate has slowed, gives lockdown a thumbs up 2020.
[33]
Modi appeals for self-imposed janata curfew on Sunday". Business standard, 2020.
[34]
Regan, Helen; Mitra, Esha; Gupta, Swati "India places millions under lockdown to fight coronavirus". CNN., 2020.
[35]
India's Coronavirus Lockdown: What It Looks Like When India's 1.3 Billion People Stay Home. 2019.
[36]
PM Modi announces extension of lockdown till 3 May. Livemint., 2020.
[37]
India has tremendous capacity in eradicating coronavirus pandemic: WHO. The Economic Times., 2020.
[38]
Gupta, Shekhar "Covid hasn't gone viral in India yet, but some in the world & at home can't accept the truth". 2020.
[39]
Covid 19 Economic Task Force: Government forms Covid-19 economic response task force, says PM Modi". The Times of India, 2020.
[40]
Narendra, P.M. PM Narendra Modi forms economic response task force, calls for 'Janata Curfew. The Economic Times, 2020.
[41]
Recovery road: At 50,000 corona cases, India's cure rate is 5th best in the world Available from: https://www.indiatoday.in/diu/story/recovery-road-50000-corona-cases-india-cure-rate-5th-best-in-world-1675934-2020-05-08
[42]
Corona-virus update lives 2020. Available from: https://www.worldometers.info/coronavirus/
[43]
Backer, J.A.; Klinkenberg, D.; Wallinga, J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill., 2020, 25(5), pii=2000062.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.2000062] [PMID: 32046819]
[44]
Novel Coronavirus (2019-nCoV) Situation Report-7 - World Health Organization., 2020,
[45]
Symptoms of Novel Coronavirus (2019-nCoV) – Centres for Disease Control and Prevention (CDC) 2019.
[46]
Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.Y.; Chen, L.; Wang, M. Presumed asymptomatic carrier transmission of COVID‐19. JAMA, 2020, 323(14), 1406-1407.
[http://dx.doi.org/10.1001/jama.2020.2565] [PMID: 32083643]
[47]
Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med, 2020.
[48]
Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[49]
Han, W.; Quan, B.; Guo, Y.; Zhang, J.; Lu, Y.; Feng, G.; Wu, Q.; Fang, F.; Cheng, L.; Jiao, N.; Li, X.; Chen, Q. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J. Med. Virol., 2020, 92(5), 461-463.
[http://dx.doi.org/10.1002/jmv.25711] [PMID: 32073161]
[50]
Chen, C.; Zhang, X.R.; Ju, Z.Y.; He, W.F. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi, 2020, 36(6), 471-475.
[51]
Bennardo, F.; Buffone, C.; Giudice, A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol., 2020, 106, 104659.
[http://dx.doi.org/10.1016/j.oraloncology.2020.104659] [PMID: 32209313]
[52]
Rose-John, S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol., 2018, 10(2), 10.
[http://dx.doi.org/10.1101/cshperspect.a028415] [PMID: 28620096]
[53]
Yang, Y.; Peng, F.; Wang, R.; Guan, K.; Jiang, T.; Xu, G.; Sun, J.; Chang, C. The deadly coronaviruses: The2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun., 2020, 109, 102434.
[54]
Coronavirus symptoms: Impact of COVID-19 on digestive health, here are the symptoms to watch out for. Available from: https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/ cdc-adds-six-new-symptoms-to-the-covid-19-list-watch-out-for-these/ photostory/
[55]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[56]
Chan, J.F.; Yuan, S.; Kok, K.H.; To, K.K.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C.C.; Poon, R.W.; Tsoi, H.W.; Lo, S.K.; Chan, K.H.; Poon, V.K.; Chan, W.M.; Ip, J.D.; Cai, J.P.; Cheng, V.C.; Chen, H.; Hui, C.K.; Yuen, K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223), 514-523.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID: 31986261]
[57]
Adhikari, S.P.; Meng, S.; Wu, Y.J.; Mao, Y.P.; Ye, R.X.; Wang, Q.Z.; Sun, C.; Sylvia, S.; Rozelle, S.; Raat, H.; Zhou, H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect. Dis. Poverty, 2020, 9(1), 29.
[http://dx.doi.org/10.1186/s40249-020-00646-x] [PMID: 32183901]
[58]
Florindo, H.F.; Kleiner, R.; Vaskovich-Koubi, D.; Acúrcio, R.C.; Carreira, B.; Yeini, E.; Tiram, G.; Liubomirski, Y.; Satchi-Fainaro, R. Immune-mediated approaches against COVID-19. Nat. Nanotechnol., 2020, 15(8), 630-645.
[http://dx.doi.org/10.1038/s41565-020-0732-3] [PMID: 32661375]
[59]
Bradley, M. The Essential Guide to The Wuhan Virus (Symptoms, Transmission and Prevention); Corona Virus, 2020.
[60]
World Health Organization Coronavirus Disease (COVID-19) Advice for the Public. Available from: https: //www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
[61]
How to Protect Yourself and others.. Centers for Disease Control and Prevention: coronavirus disease 2019 (COVID-19) - how to protect yourself 2020.
[62]
Coronavirus Preventions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/about/prevention.html
[63]
AYUSH reiterates immunity boosting measures for self-care during COVID 19 crises 2020. Available from: https://pib.gov.in/newsite/PrintRelease.aspx?relid=201167
[64]
India fights Coronavirus - 2019 Available from: https://www.mygov.in/covid-19/
[65]
Wang, H.; Wang, S.; Yu, K. COVID-19 infection epidemic: the medical management strategies in Heilongjiang Province, China. Crit. Care, 2020, 24(1), 107.
[http://dx.doi.org/10.1186/s13054-020-2832-8] [PMID: 32188482]
[66]
Gray, A. The hunt for an effective treatment for COVID-19. Pharm. J., 2020, 304(7936)
[http://dx.doi.org/10.1211/PJ.2020.20207883]
[67]
Di Savarino, A.; Trani, L.; Donatelli, I.; Cauda, R.; Cassone, A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis., 2006, 6, 67-69.
[http://dx.doi.org/10.1016/S1473-3099(06)70361-9]
[68]
Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Tissot Dupont, H.; Honoré, S.; Colson, P.; Chabrière, E.; La Scola, B.; Rolain, J.M.; Brouqui, P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020, 56(1), 105949.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[69]
Yan, Y.; Zou, Z.; Sun, Y.; Li, X.; Xu, K.F.; Wei, Y.; Jin, N.; Jiang, C. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res., 2013, 23(2), 300-302.
[http://dx.doi.org/10.1038/cr.2012.165] [PMID: 23208422]
[70]
Rolain, J.M.; Colson, P.; Raoult, D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents, 2007, 30(4), 297-308.
[http://dx.doi.org/10.1016/j.ijantimicag.2007.05.015] [PMID: 17629679]
[71]
Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2, 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[72]
Lim, J.; Jeon, S.; Shin, H.Y.; Kim, M.J.; Seong, Y.M.; Lee, W.J.; Choe, K.W.; Kang, Y.M.; Lee, B.; Park, S.J. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of lopinavir/ ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci., 2020, 35(6), e79.
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID: 32056407]
[73]
Prajapat, M.; Sarma, P.; Shekhar, N.; Avti, P.; Sinha, S.; Kaur, H.; Kumar, S.; Bhattacharyya, A.; Kumar, H.; Bansal, S.; Medhi, B. Drug targets for corona virus: A systematic review. Indian J. Pharmacol., 2020, 52(1), 56-65.
[http://dx.doi.org/10.4103/ijp.IJP_115_20] [PMID: 32201449]
[74]
Wang, Z.; Chen, X.; Lu, Y.; Chen, F.; Zhang, W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci. Trends, 2020, 14(1), 64-68.
[http://dx.doi.org/10.5582/bst.2020.01030] [PMID: 32037389]
[75]
Sheahan, T.P.; Sims, A.C.; Graham, R.L.; Menachery, V.D.; Gralinski, L.E.; Case, J.B. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med., 2017, 9(396), eaal3653.
[76]
Al-Tawfiq, JA; Al-Homoud, AH Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis, 2020.
[77]
Wang, M.; Cao, R.; Zhang, L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2019, 30(3), 269-271.
[78]
Holshue, M.L.; DeBolt, C.; Lindquist, S. Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel corona virus in the United States. N. Engl. J. Med., 2020, 382(10), 929-936.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[79]
Kujawski, S.A.; Wong, K.; Collins, J.P. First 12 patients with corona virus disease 2019(COVID-19) in the United States. Med Rxiv, 2020.
[80]
Sheahan, T.P.; Sims, A.C.; Leist, S.R.; Schäfer, A.; Won, J.; Brown, A.J.; Montgomery, S.A.; Hogg, A.; Babusis, D.; Clarke, M.O.; Spahn, J.E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J.Y.; Cihlar, T.; Jordan, R.; Denison, M.R.; Baric, R.S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 2020, 11(1), 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[81]
Wenzel, R.P.; Edmond, M.B. Managing SARS amidst uncertainty. N. Engl. J. Med., 2003, 348(20), 1947-1948.
[http://dx.doi.org/10.1056/NEJMp030072] [PMID: 12748313]
[82]
Elfiky, A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci., 2020, 248, 117477.
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
[83]
Khamitov, R.A.; Loginova, S.Ia.; Shchukina, V.N.; Borisevich, S.V.; Maksimov, V.A.; Shuster, A.M. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr. Virusol., 2008, 53(4), 9-13. [inRussian].
[PMID: 18756809]
[84]
Kadam, R.U.; Wilson, I.A. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci USA, 2017, 114(2), 206-214.
[http://dx.doi.org/10.1073/pnas.1617020114]
[85]
Wang, Z.; Yang, B.; Li, Q.; Wen, L.; Zhang, R.; Wen, L. Clinical Features of 69 cases with corona-virus disease 2019 in Wuhan, China. Clin. Infect. Dis., 2020, 71(15), 769-777.
[http://dx.doi.org/10.1093/cid/ciaa272] [PMID: 32176772]
[86]
GR, K. Immune Defenses.Medical Microbiology, 4th ed; S, B., Ed. University of Texas Medical Branch at Galveston: Galveston, TX, 1996.
[87]
Mulangu, S.; Dodd, L.E.; Davey, R.T., Jr; Tshiani Mbaya, O.; Proschan, M.; Mukadi, D.; Lusakibanza Manzo, M.; Nzolo, D.; Tshomba Oloma, A.; Ibanda, A.; Ali, R.; Coulibaly, S.; Levine, A.C.; Grais, R.; Diaz, J.; Lane, H.C.; Muyembe-Tamfum, J.J.; Sivahera, B.; Camara, M.; Kojan, R.; Walker, R.; Dighero-Kemp, B.; Cao, H.; Mukumbayi, P.; Mbala-Kingebeni, P.; Ahuka, S.; Albert, S.; Bonnett, T.; Crozier, I.; Duvenhage, M.; Proffitt, C.; Teitelbaum, M.; Moench, T.; Aboulhab, J.; Barrett, K.; Cahill, K.; Cone, K.; Eckes, R.; Hensley, L.; Herpin, B.; Higgs, E.; Ledgerwood, J.; Pierson, J.; Smolskis, M.; Sow, Y.; Tierney, J.; Sivapalasingam, S.; Holman, W.; Gettinger, N.; Vallée, D.; Nordwall, J. PALM Writing Group; PALM Consortium Study Team. Jr., Tshiani, M.; baya, O.; Proschan, M.; Mukadi, D. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med., 2019, 381(24), 2293-2303.
[http://dx.doi.org/10.1056/NEJMoa1910993] [PMID: 31774950]
[88]
Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; Ying, T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect., 2020, 9(1), 382-385.
[http://dx.doi.org/10.1080/22221751.2020.1729069] [PMID: 32065055]
[89]
AYUSH Ministry launches clinical trials of Ayurvedic medicines against COVID-19. Available from: https://www.timesnownews.com/health/article/ayush-ministry-launches-clinical-trials-of-ayurvedic-medicines-against-covid19/588662
[90]
Zimmer, K. First Antibody Trial Launched in COVID-19 Patients. Available from: https://www.the-scientist.com/news-opinion/first-antibody-trial-launched-in-covid-19-patients--67604

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy